Vaxcyte, Inc (PCVX) Announces Proposed Stock and Warrant Offering
- Wall Street rallies as Fed minutes meet expectations
- NVIDIA Shares Drop 6% on Disappointing Guidance, While Q1 Earnings Beat
- Apple (AAPL) Reportedly Behind Schedule in Development of the New iPhone, Analyst Cuts Price Target on Risk to June Quarter iPhone Revenue
- Oil edges higher on tight supply, rising U.S. refining activity
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. Cantor is acting as lead manager for the offering. Needham & Company is acting as co-manager for the offering.
A shelf registration statement relating to the offered securities was filed with the Securities and Exchange Commission (SEC), and was automatically effective upon filing on July 2, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus relating to this offering may be obtained, when available, from BofA Securities NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, North Carolina 29255 or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at 1-877-821-7388, or by email at [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 1-888-474-0200 or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Geovax Labs Inc. (GOVX) Prices $20M Direct and PIPE Offerings at $1.65/sh
- Chinook Therapeutics (KDNY) Announces Proposed Stock Offering, Size not Disclosed
- Mid-Southern Savings Bank (MSVB) Expands Share Buyback Plan by Additional 142K Shares
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesJefferies & Co, Needham & Company
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!